Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
äŒæ¥ã³ãŒãTEM
äŒç€ŸåTempus AI Inc
äžå Žæ¥May 30, 2025
æé«çµå¶è²¬ä»»è
ãCEOãLefkofsky (Eric P)
åŸæ¥å¡æ°2400
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«May 30
æ¬ç€Ÿæåšå°600 West Chicago Avenue
éœåžCHICAGO
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·60654
é»è©±çªå·18335144187
ãŠã§ããµã€ãhttps://investors.tempus.com/
äŒæ¥ã³ãŒãTEM
äžå Žæ¥May 30, 2025
æé«çµå¶è²¬ä»»è
ãCEOãLefkofsky (Eric P)